Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Expected to Post Earnings of -$1.22 Per Share


Share on StockTwits

Wall Street analysts expect Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to post ($1.22) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($0.93) and the lowest estimate coming in at ($1.80). Ultragenyx Pharmaceutical reported earnings of ($2.04) per share during the same quarter last year, which would suggest a positive year over year growth rate of 40.2%. The business is scheduled to issue its next earnings results on Wednesday, May 5th.

On average, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($4.81) per share for the current financial year, with EPS estimates ranging from ($5.69) to ($3.88). For the next financial year, analysts forecast that the firm will report earnings of ($4.21) per share, with EPS estimates ranging from ($6.04) to ($1.22). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Ultragenyx Pharmaceutical.

Several equities analysts have recently issued reports on the company. Piper Sandler boosted their target price on Ultragenyx Pharmaceutical from $165.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, February 12th. TheStreet upgraded shares of Ultragenyx Pharmaceutical from a “d” rating to a “c-” rating in a report on Tuesday, February 16th. JPMorgan Chase & Co. cut shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $165.00 target price for the company. in a research report on Friday, February 12th. Robert W. Baird boosted their price target on shares of Ultragenyx Pharmaceutical from $110.00 to $165.00 and gave the company an “outperform” rating in a research report on Monday, January 11th. Finally, Stifel Nicolaus began coverage on shares of Ultragenyx Pharmaceutical in a report on Monday, March 1st. They issued a “buy” rating and a $179.00 price objective for the company. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. Ultragenyx Pharmaceutical has a consensus rating of “Hold” and an average price target of $132.50.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 30,000 shares of the firm’s stock in a transaction dated Monday, March 1st. The shares were sold at an average price of $141.80, for a total transaction of $4,254,000.00. Following the completion of the sale, the chief executive officer now directly owns 596,941 shares in the company, valued at approximately $84,646,233.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Theodore Alan Huizenga sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, March 8th. The stock was sold at an average price of $120.69, for a total transaction of $362,070.00. The disclosure for this sale can be found here. Insiders have sold 54,245 shares of company stock valued at $7,637,704 in the last quarter. 8.20% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of RARE. AGF Investments LLC bought a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at $25,000. Point72 Hong Kong Ltd bought a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at about $57,000. Captrust Financial Advisors bought a new position in Ultragenyx Pharmaceutical during the 4th quarter valued at about $75,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $112,000. Finally, Harvest Fund Management Co. Ltd grew its stake in shares of Ultragenyx Pharmaceutical by 15.9% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 888 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 122 shares during the period.

NASDAQ RARE opened at $105.27 on Thursday. Ultragenyx Pharmaceutical has a 1 year low of $50.22 and a 1 year high of $179.65. The stock has a market capitalization of $7.05 billion, a PE ratio of -23.98 and a beta of 2.19. The business’s 50-day moving average is $125.80 and its 200 day moving average is $125.00.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders.

Recommended Story: How is net asset value different from market price?

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.